Editverse · Clinical Decision Tools
Free MELD-Na Calculator (2026)
The MELD-Na calculator estimates the severity of chronic liver disease from four laboratory values — bilirubin, INR, creatinine, and sodium — and reports two related numbers: the original MELD score and the sodium-adjusted MELD-Na score. Both were developed to predict short-term mortality in patients with cirrhosis and other chronic liver disease, and MELD-Na in particular is widely used to communicate how sick a patient is when discussing transplant priority, admission triage, or prognosis with a hepatology or transplant team. It is built for hepatologists, transplant physicians, internists, intensivists, and trainees who need a fast, reproducible severity estimate from labs already on the chart. One note up front: U.S. transplant waitlist allocation now runs on the newer MELD 3.0 formula, adopted by UNOS in 2023 — this calculator implements the well-established 2016 MELD-Na formula for education and general severity estimation, not as a substitute for the certified UNOS allocation tool.
Clinical decision-support aid, not a substitute for clinical judgment. These tools implement published scoring criteria for education and workflow support. They are not a medical device and have not been reviewed by the FDA or any regulatory body. Every result should be interpreted by a qualified clinician in the context of the full clinical picture, not used as a standalone diagnostic or treatment decision.
Liver disease severity
MELD-Na
Enter bilirubin, INR, creatinine, and sodium below. Values are automatically floored, capped, and bounded exactly as the original algorithm specifies, so the displayed score matches what a lab-integrated MELD-Na calculation would produce.
Kamath PS, et al. Hepatology. 2001;33(2):464–470 (original MELD) · Kamath PS, et al. Hepatology. 2007;45(3):797–805 (sodium inclusion) · Kim WR, et al. Gastroenterology. 2021;161(6):1887–1895 (MELD 3.0, current UNOS allocation formula).
Worked example
Consider a patient with a total bilirubin of 2.5 mg/dL, an INR of 1.5, a creatinine of 1.8 mg/dL, and a sodium of 130 mEq/L, not on dialysis. None of the three floored values — bilirubin, INR, creatinine — need adjustment, since all are already above 1.0, and the creatinine is below the 4.0 mg/dL cap, so the raw MELD calculation runs on the measured numbers directly. That yields a MELD score of 20.
Because sodium is below the normal reference range, the MELD-Na adjustment adds more weight to the score: the same patient’s MELD-Na comes out to 25. Entering these exact four values into the calculator above reproduces both numbers. The five-point gap between MELD and MELD-Na in this case illustrates why the sodium correction matters clinically — the hyponatremia adds meaningfully to the estimated 90-day mortality risk used in transplant-priority discussions, information the unadjusted MELD alone would have understated.
Methods, assumptions & limitations
Methods sentence. Liver disease severity was quantified using the MELD-Na score, calculated as MELD = 3.78×ln(bilirubin, mg/dL) + 11.2×ln(INR) + 9.57×ln(creatinine, mg/dL) + 6.43, with bilirubin, INR, and creatinine each floored at 1.0 and creatinine capped at 4.0 mg/dL (or set to 4.0 if the patient received hemodialysis at least twice in the prior week, or 24 hours of continuous veno-venous hemodialysis), then sodium-adjusted as MELD-Na = MELD + 1.32×(137−Na) − [0.033×MELD×(137−Na)] with serum sodium bounded to 125–137 mEq/L, and the final score bounded to a range of 6–40 (Kamath et al., 2001; Kamath et al., 2007).
When not to use this calculator. It is intended for estimating chronic liver disease severity and informing transplant-priority discussions — it is not designed or validated for staging acute liver failure, and a single MELD-Na value should never be read in isolation from the rest of the clinical picture. Most importantly, it is not a substitute for the certified UNOS MELD 3.0 calculator, which is the score actually used for U.S. liver transplant waitlist allocation as of 2023: MELD 3.0 adds serum albumin, an interaction term between sodium and albumin, a small constant favoring female candidates, and a sex–creatinine interaction term, refinements aimed at correcting a historical underestimation of disease severity in female candidates. Any real transplant-listing decision should use that certified tool and current UNOS/OPTN policy, not this or any other educational calculator.
Common questions
What is the difference between MELD and MELD-Na?
MELD is the original three-variable score (bilirubin, INR, creatinine) described by Kamath and colleagues in 2001. MELD-Na adds a correction for serum sodium, introduced after later research showed that hyponatremia is an independent predictor of mortality in patients with cirrhosis not fully captured by the original three labs. In practice, MELD-Na is equal to or higher than the plain MELD score whenever sodium is below 137 mEq/L — the more pronounced the hyponatremia within the bounded 125–137 mEq/L range, the larger the gap — and identical to MELD when sodium is at or above 137 mEq/L.
Is MELD-Na still used for liver transplant allocation in 2026?
No, not directly. UNOS/OPTN moved U.S. adult liver transplant waitlist allocation to MELD 3.0 in July 2023. MELD 3.0 keeps the same bilirubin/INR/creatinine/sodium backbone but adds serum albumin, a sodium–albumin interaction term, a small constant favoring female candidates, and a sex–creatinine interaction term — changes intended to correct systematic disadvantages the original MELD and MELD-Na formulas created for women and for patients with low albumin. MELD-Na remains well validated and widely used for general severity estimation, research, and non-allocation clinical discussions, but any actual transplant-listing decision should run through the certified UNOS MELD 3.0 calculator and current OPTN policy, not this page.
What do MELD-Na score ranges mean in practice?
There is no single cutoff that applies to every clinical situation, but broadly: scores under 10 generally reflect compensated, lower-severity liver disease; scores from the teens into the high 20s reflect progressively more advanced disease and correspondingly higher estimated 90-day mortality without transplant; and scores of 30 and above sit at the most severe end of the spectrum, where transplant evaluation is typically already well underway for a listed candidate. Because the score is bounded between 6 and 40, a displayed value at either edge may understate how far below 6 or above 40 the underlying calculation actually fell — treat the bounds as a floor and ceiling on the score’s precision, not as evidence a patient’s true severity is capped.
Primary references
- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470.
- Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805.
- Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887–1895.
Related research support
Studying liver disease severity or transplant-oncology outcomes?
If MELD-Na is part of a hepatocellular carcinoma outcomes analysis, a transplant-oncology cohort study, or any project drawing on SEER or a similar cancer registry, Editverse’s SEER Cancer Outcomes Study service handles the registry-linked survival analysis and manuscript-ready methods and results sections end to end.